Alain Spatz

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
  2. ncbi Primary yolk sac tumor of the endometrium: a case report and review of the literature
    A Spatz
    Department of Pathology, Institut Gustave Roussy, Villejuif, 94805, France
    Gynecol Oncol 70:285-8. 1998
  3. ncbi The role of the EORTC pathologist in clinical trials: achievements and perspectives. European Organisation for Research and Treatment of Cancer
    Alain Spatz
    Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 38:S120-4. 2002
  4. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
  5. ncbi Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas
    A Spatz
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 39:1861-5. 2003
  6. doi Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    Jean Philippe Arnault
    Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
    Clin Cancer Res 18:263-72. 2012
  7. doi Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
    Caroline Kannengiesser
    Service de Génétique and CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    Mol Oncol 1:425-30. 2008
  8. ncbi BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
    Christian Monnerat
    Department of Genetics, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Fam Cancer 6:453-61. 2007
  9. doi Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    Caroline Robert
    Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
    J Am Acad Dermatol 60:299-305. 2009
  10. doi Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008

Detail Information

Publications33

  1. ncbi Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
    Bruce Elliott
    Royal Surrey County Hospital Guildford, Guildford, United Kingdom
    Clin Cancer Res 13:3825-30. 2007
    ..The aim of this study was to investigate the prognostic importance of the maximal density of mature DCs in SLNs...
  2. ncbi Primary yolk sac tumor of the endometrium: a case report and review of the literature
    A Spatz
    Department of Pathology, Institut Gustave Roussy, Villejuif, 94805, France
    Gynecol Oncol 70:285-8. 1998
    ..On the basis of the small number of cases reported, such tumors appear to have clinical and pathological features similar to their ovarian counterparts...
  3. ncbi The role of the EORTC pathologist in clinical trials: achievements and perspectives. European Organisation for Research and Treatment of Cancer
    Alain Spatz
    Department of Pathology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 38:S120-4. 2002
    ..In addition, translational research is a resource-consuming activity that necessitates an adequate financial flow to create a proper infrastructure at least for sponsored trials to the participating pathology departments and committees...
  4. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  5. ncbi Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas
    A Spatz
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 39:1861-5. 2003
    ....
  6. doi Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1
    Jean Philippe Arnault
    Department of Medical Oncology and Pathology, Institute Gustave Roussy, Villejuif, France
    Clin Cancer Res 18:263-72. 2012
    ..We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib...
  7. doi Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas
    Caroline Kannengiesser
    Service de Génétique and CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    Mol Oncol 1:425-30. 2008
    ....
  8. ncbi BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
    Christian Monnerat
    Department of Genetics, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Fam Cancer 6:453-61. 2007
    ..Our goal was to estimate the involvement of "high risk" genes in patients presenting these two neoplasia, selected irrespectively from family history and age at diagnosis...
  9. doi Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    Caroline Robert
    Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
    J Am Acad Dermatol 60:299-305. 2009
    ..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms...
  10. doi Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
    ..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor...
  11. ncbi F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm
    Eve Maubec
    Department of Dermatology, Institut Gustave Roussy, Villejuif Cedex, France
    Melanoma Res 17:147-54. 2007
    ..Sentinel lymph node biopsy remains the technique of choice for the most accurate initial staging...
  12. ncbi Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  13. ncbi CDKN2A as a uveal and cutaneous melanoma susceptibility gene
    Caroline Kannengiesser
    Service de Genetique, Institut Gustave Roussy, Villejuif, France
    Genes Chromosomes Cancer 38:265-8. 2003
    ..Immunohistochemistry performed on the UM tissue block revealed loss of CDKN2A protein staining in tumor cells. These observations demonstrate that CDKN2A is also a UM susceptibility gene...
  14. pmc Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period
    Nathalie Lassau
    Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Cancer Imaging 6:24-9. 2006
    ..To study the value of high-frequency sonography (HFS) and colour Doppler sonography (CDS) in evaluating the 5 year metastatic potential of primary cutaneous melanomas (CM)...
  15. ncbi Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma
    Mojgan Movassagh
    Immunology Institut National de la Santé et de la Recherche Médicale ERM0208 and Immunotherapy Unit, Department of Pathology, Dermatology Unit, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Cancer Res 64:2192-8. 2004
    ....
  16. ncbi Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene
    Sophie Queille
    Laboratoire Génomes et Cancers, FRE2939 CNRS, Institut Gustave Roussy, PRII, 39 Rue Camille Desmoulins 94805 Villejuif, France
    Carcinogenesis 28:724-31. 2007
    ....
  17. ncbi Reliability of the histopathologic diagnosis of malignant melanoma in childhood
    Janine Wechsler
    Department of Pathology, Henri Mondor Hospital, F 94010 Créteil Cedex, France
    Arch Dermatol 138:625-8. 2002
    ..To assess interrater reliability in the diagnosis of malignant melanoma in children...
  18. pmc Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  19. ncbi Soft tissue sarcomas. Case 3. Gastrointestinal stromal tumor and Carney's triad
    Alain Spatz
    Department of Pathology, Institute Gustave Roussy, Villejuif, France
    J Clin Oncol 22:2029-31. 2004
  20. ncbi The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma
    Raymond L Barnhill
    Department of Dermatology, George Washington University Medical Center, Washington, DC, USA
    J Cutan Pathol 32:268-73. 2005
    ..When both TU and MR are included in the same analysis, MR appears to be the more important than TU and TU loses its significance as an independent prognostic factor...
  21. ncbi Pathologic staging of melanoma
    Dirk J Ruiter
    Department of Pathology, University Medical Center St Radboud, Nijmegen, The Netherland
    Semin Oncol 29:370-81. 2002
    ..Molecular markers that may reflect aggressive behavior of the primary melanoma also are described. Finally, pathologic examination of SLNs is addressed with emphasis on the efficacy of various microstaging approaches...
  22. ncbi The development of optimal pathological assessment of sentinel lymph nodes for melanoma
    Martin G Cook
    Department of Histopathology, Royal Surrey County Hospital, Guildford, UK
    J Pathol 200:314-9. 2003
    ..The evolved protocol described here has been adopted by the EORTC as the standard procedure for pathological handling of sentinel lymph nodes for melanoma when SLN status is a criterion in their clinical trials or studies...
  23. ncbi Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma
    Veronique Winnepenninckx
    Department of Morphology and Molecular Pathology, University Hospitals, Katholieke Universiteit Leuven KUL, Leuven, Belgium
    Mod Pathol 19:1170-80. 2006
    ....
  24. ncbi Tyrosine kinase inhibition and grey hair
    Caroline Robert
    Lancet 361:1056. 2003
  25. doi Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
    Alexander M M Eggermont
    Erasmus University Medical Center, Rotterdam, Netherlands
    Lancet 372:117-26. 2008
    ..Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability...
  26. ncbi Dendritic cell derived-exosomes: biology and clinical implementations
    Nathalie Chaput
    ERM0208 Institut National de la Sante et de la Recherche Medicale, Faculté de Médecine Paris Sud Université, Paris XI, France
    J Leukoc Biol 80:471-8. 2006
    ..Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients...
  27. ncbi Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group
    Martin G Cook
    Department of Histopathology, Royal Surrey County Hospital, Guildford, UK
    J Pathol 197:188-93. 2002
    ..This implies that VGP may require redefinition and that junctional expansion nodules and melanomatous follicular invasion may be variants of VGP...
  28. ncbi Factors to keep in mind when introducing virtual microscopy
    Katharina Glatz-Krieger
    Institute for Pathology, University Hospital of Basel, Basel, Switzerland
    Virchows Arch 448:248-55. 2006
    ..These systems differ in speed, image quality, compatibility, viewer functionalities and price. This paper gives an overview of the factors to keep in mind when introducing virtual microscopy...
  29. ncbi X-chromosome genetics and human cancer
    Alain Spatz
    Institut Gustave Roussy and UMR 8125 CNRS, 94805 Villejuif, France
    Nat Rev Cancer 4:617-29. 2004
  30. ncbi Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families
    Valerie Chaudru
    Institut National de la Santé et Recherche Médicale et Université d Evry, Evry, France
    J Natl Cancer Inst 96:785-95. 2004
    ..We assessed the role of these factors on melanoma risk in two types of families: families ascertained through melanoma probands but unselected by family history and melanoma-prone families...
  31. ncbi Comparative genomic hybridization analysis of hereditary swine cutaneous melanoma revealed loss of the swine 13q36-49 chromosomal region in the nodular melanoma subtype
    Françoise Apiou
    Institut Curie Recherche, Paris, France
    Int J Cancer 110:232-8. 2004
    ....
  32. ncbi Clinical and histopathological characterization of cutaneous melanomas in the melanoblastoma-bearing Libechov minipig model
    Silvia Vincent-Naulleau
    Laboratoire de Radiobiologie et Etude du Génome, CEA INRA, Jouy en Josas Cedex, France
    Pigment Cell Res 17:24-35. 2004
    ....
  33. ncbi Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis
    Claire Lugassy
    J Invest Dermatol 119:703-4. 2002